Multimarker analysis of circulating tumor cells in peripheral blood of metastatic breast cancer patients: A step forward in personalized medicine

Breast Care

Volumn 7, Issue 1, 2012, Pages 7-12

  De Albuquerque, Andreia ^a,b   Kaul, Sepp ^b   Breier, Georg ^a   Krabisch, Petra ^c   Fersis, Nikos ^c  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Zentrum fur Diagnostik   (Germany)

^c KLINIKUM CHEMNITZ   (Germany)

Author keywords

Circulating tumor cells; Gene expression analysis; Immunomagnetic separation; Metastatic breast cancer; Real time reverse transcription polymerase chain reaction

Indexed keywords

BIRC5 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; KRT19 PROTEIN; MAMMAGLOBIN A; MUCIN 1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD; BREAST CANCER; CANCER CELL; CANCER PATIENT; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; MARKER GENE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR GENE;

EID: 84858672404     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000336548     Document Type: Article

References (29)

1. Liu MC, Shields PG, Warren RD, Cohen P, Wilkinson M, Ottaviano YL, et al.: Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009;27:5153-5159.
2. Amadori A, Rossi E, Zamarchi R, Carli P, Pastorelli D, Jirillo A: Circulating and disseminated tumor cells in the clinical management of breast cancer patients: unanswered questions. Oncology 2009;76:375-386.
3. Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, et al.: Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer 2008;113:2422-2430.
4. Greil R: The dark side of the moon-the side effects of therapy in a dynamic era of breast cancer management. Breast Care 2009;4:144-147.
5. Citron ML: Dose-dense chemotherapy: principles, clinical results and future perspectives. Breast Care 2008;3:251-255.
6. Gazzaniga P, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, et al.: Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. Int J Cancer 2010;126:2437-2447.
7. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al.: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-1430.
8. Fehm T, Müller V, Alix-Panabières C, Pantel K: Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res 2008;10(suppl 1):S1.
9. Miller MC, Doyle GV, Terstappen LW: Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010;2010:617421.
10. Smerage JB, Hayes DF: The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer 2006;94:8-12. (Pubitemid 43088533)
11. Bitisik O, Saip P, Saglam S, Derin D, Dalay N: Mammaglobin and maspin transcripts in blood may reflect disease progression and the effect of therapy in breast cancer. Genet Mol Res 2010;9:97-106.
12. Mostert B, Sleijfer S, Foekens JA, Gratama JW: Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 2009;35:463-474.
13. Becker S, Becker-Pergola G, Banys M, Krawczyk N, Wallwiener D, Solomayer E, et al.: Evaluation of a RT-PCR based routine screening tool for the detection of disseminated epithelial cells in the bone marrow of breast cancer patients. Breast Cancer Res Treat 2009;117:227-233.
14. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al.: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004;101:9393-9398. (Pubitemid 38812885)
15. Lin YS, Zhong XY, Hohaus S, Kaul S, Haas R: Detection of tumor cells in leukapheresis products from patients with breast cancer using immunocytochemical staining method. Arch Gynecol Obstet 2000;263:119-125. (Pubitemid 30153706)
16. de Albuquerque A, Kaul S, Fersis N, Ernst D, Teubner A, Breier G: 1327 Real-time risk evaluation of metastasis using circulating tumor cells. Eur J Cancer 2009;7(suppl 2):147.
17. Ernst D, Teubner A, de Albuquerque A, Kaul S, Fersis N, Boese-Landgraf J: 6104 Circulating tumour cells in colorectal cancer: multi-gene expression analysis during chemotherapy. Eur J Cancer 2009;7(suppl 2):354.
18. Teubner A, Ernst D, de Albuquerque A, Kaul S, Fersis N, Stölzel U: 6636 Genetic profiling of circulating tumor cells in the blood of patients with local advanced or metastatic upper gastrointestinal carcinomas. Eur J Cancer 2009;7(suppl 2):400.
19. Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N, et al.: A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int J Cancer 2006;119:1654-1659. (Pubitemid 44258772)
20. Bartek J, Taylor-Papadimitriou J, Miller N, Millis R: Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int J Cancer 1985;36:299-306. (Pubitemid 16250991)
21. Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, et al.: Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann Oncol 2007;18:851-858. (Pubitemid 47054081)
22. Hiraga Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al.: Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998;55:307-319. (Pubitemid 28279672)
23. Münz M, Zeidler R, Gires O: The tumour-associated antigen EpCAM upregulates the fatty acid binding protein E-FABP. Cancer Lett 2005;225:151-157. (Pubitemid 40732778)
24. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA, et al.: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-5824. (Pubitemid 39095582)
25. Sankpal NV, Willman MW, Fleming TP, Mayfield JD, Gillanders WE: Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res 2009;69:753-757.
26. Span PN, Sweep FCGJ, Wiegerinck ETG, Tjan-Heijnen VCG, Manders P, Beex LVAM, et al.: Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004;50:1986-1993. (Pubitemid 39425834)
27. Schütz F: Targeted therapy: Can it substitute for chemotherapy? Breast Care 2008;3:257-261.
28. Harbeck N, Jakesz R, Thomssen C: The future of breast cancer management. Breast Care 2008;3:381-382.
29. Thomssen C: Perspectives on breast cancer management: tailoring treatment to the individual patient. Breast Care 2008;3(suppl 1):21-23. (Pubitemid 351777543)